Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?

Tsilogianni Z, Baker JR, Papaporfyriou A, Papaioannou AI, Papathanasiou E, Koulouris NG, Daly L, Ito K, Hillas G, Papiris S, Bakakos P, Loukides S.

J Clin Med. 2020 Feb 9;9(2). pii: E473. doi: 10.3390/jcm9020473.

3.

Pharmacological treatment of stable COPD: need for a simplified approach.

Hillas G, Papaporfyriou A, Dimakou K, Papaioannou AI.

Postgrad Med. 2020 Jan 11:1-6. doi: 10.1080/00325481.2019.1706996. [Epub ahead of print]

PMID:
31852408
4.

Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis.

Papiris SA, Georgakopoulos A, Papaioannou AI, Pianou N, Kallergi M, Kelekis NL, Gialafos H, Manali ED, Chatziioannou S.

Expert Rev Respir Med. 2020 Feb;14(2):229-238. doi: 10.1080/17476348.2020.1684902. Epub 2019 Oct 29.

PMID:
31647341
5.

18F-FDG PET/CT in Pulmonary Sarcoidosis:Quantifying Inflammation by the TLG index.

Papiris SA, Manali ED, Pianou NK, Kallergi M, Papaioannou AI, Georgakopoulos A, Malagari K, Kelekis NL, Gialafos H, Chatziioannou S.

Expert Rev Respir Med. 2020 Jan;14(1):103-110. doi: 10.1080/17476348.2020.1682997. Epub 2019 Oct 24.

PMID:
31626563
6.

Mycophenolate mofetil as an alternative treatment in sarcoidosis.

Papiris S, Stagaki E, Papadaki G, Kolilekas L, Korbila I, Apollonatou V, Kallieri M, Gialafos H, Chatziioannou S, Papaioannou AI, Manali ED.

Pulm Pharmacol Ther. 2019 Oct;58:101840. doi: 10.1016/j.pupt.2019.101840. Epub 2019 Sep 10.

PMID:
31518648
7.

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison.

Papiris SA, Tsirigotis P, Kannengiesser C, Kolilekas L, Gkirkas K, Papaioannou AI, Revy P, Giouleka P, Papadaki G, Kagouridis K, Pappa V, Borie R, Boileau C, Bouros D, Crestani B, Manali ED.

Respir Res. 2019 Aug 13;20(1):182. doi: 10.1186/s12931-019-1151-6.

8.

Inflammatory profile in optimally treated patients with adult versus early-onset asthma.

Papaporfyriou A, Papaioannou AI, Hillas G, Konstantelou E, Tseliou E, Koulouris N, Papiris S, Bakakos P, Kostikas K, Loukides S.

Postgrad Med. 2019 Jun;131(5):324-329. doi: 10.1080/00325481.2019.1600884. Epub 2019 Apr 4.

PMID:
30920326
9.

Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation.

Price DB, Yang S, Ming SWY, Hardjojo A, Cabrera C, Papaioannou AI, Loukides S, Kritikos V, Bosnic-Anticevich SZ, Carter V, Dorinsky PM.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 13;13:3937-3946. doi: 10.2147/COPD.S174371. eCollection 2018.

10.

Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits.

Papaioannou AI, Diamant Z, Bakakos P, Loukides S.

Respir Med. 2018 Sep;142:15-22. doi: 10.1016/j.rmed.2018.07.006. Epub 2018 Jul 17. Review.

PMID:
30170796
11.

Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?

Papaioannou AI, Loukides S, Kostikas K.

EBioMedicine. 2018 Sep;35:6-7. doi: 10.1016/j.ebiom.2018.08.013. Epub 2018 Aug 14. No abstract available.

12.

Acrometastasis due to lung adenocarcinoma.

Apollonatou V, Loukides S, Papaioannou AI, Papiris S.

Adv Respir Med. 2018;86(2):97-100. doi: 10.5603/ARM.2018.0013.

13.

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Petta V, Loukides S, Kostikas K, Papaioannou AI, Papatheodorou G, Cholidou K, Tomos I, Papiris S, Koulouris NG, Bakakos P.

J Thorac Dis. 2018 Feb;10(2):740-748. doi: 10.21037/jtd.2018.01.45.

14.

An algorithmic approach for the treatment of severe uncontrolled asthma.

Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M.

ERJ Open Res. 2018 Mar 6;4(1). pii: 00125-2017. doi: 10.1183/23120541.00125-2017. eCollection 2018 Jan. Review.

15.

Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation.

Papaioannou AI, Konstantelou E, Papaporfyriou A, Bartziokas K, Spathis A, Bakakos P, Loukides S, Koulouris N, Papiris S, Kostikas K.

Lung. 2018 Apr;196(2):201-205. doi: 10.1007/s00408-018-0099-5. Epub 2018 Feb 14.

PMID:
29445934
16.

Using simple blood count for the diagnosis of pulmonary embolism in chronic obstructive pulmonary disease exacerbations: are we there yet?

Papaioannou AI, Papiris S, Kostikas K.

Pol Arch Intern Med. 2018 Jan 31;128(1):7-8. doi: 10.20452/pamw.4195. Epub 2018 Jan 29. No abstract available.

17.

Ability of using different dry powder inhalers during COPD exacerbations.

Papaioannou AI, Herodotou Y, Tomos I, Apollonatou V, Verykokou G, Papathanasiou E, Manali ED, Loukides S, Papiris SA.

Pulm Pharmacol Ther. 2018 Feb;48:211-216. doi: 10.1016/j.pupt.2017.12.007. Epub 2017 Dec 19.

PMID:
29277688
18.

Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study.

Papaioannou AI, Kostikas K, Papaporfyriou A, Angelakis L, Papathanasiou E, Hillas G, Mazioti A, Bakakos P, Koulouris N, Papiris S, Loukides S.

COPD. 2017 Dec;14(6):635-640. doi: 10.1080/15412555.2017.1386644. Epub 2017 Nov 3.

PMID:
29099646
19.

The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.

Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, Loukides S, Papiris S, Koulouris N, Bakakos P.

Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.

PMID:
28863927
20.

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits.

Vasilopoulou M, Papaioannou AI, Kaltsakas G, Louvaris Z, Chynkiamis N, Spetsioti S, Kortianou E, Genimata SA, Palamidas A, Kostikas K, Koulouris NG, Vogiatzis I.

Eur Respir J. 2017 May 25;49(5). pii: 1602129. doi: 10.1183/13993003.02129-2016. Print 2017 May.

21.

Serum periostin in patients hospitalized for COPD exacerbations.

Konstantelou E, Papaioannou AI, Loukides S, Bartziokas K, Papaporfyriou A, Papatheodorou G, Bakakos P, Papiris S, Koulouris N, Kostikas K.

Cytokine. 2017 May;93:51-56. doi: 10.1016/j.cyto.2017.05.007. Epub 2017 May 13.

PMID:
28511944
22.

Decreased Serum Sirtuin-1 in COPD.

Yanagisawa S, Papaioannou AI, Papaporfyriou A, Baker JR, Vuppusetty C, Loukides S, Barnes PJ, Ito K.

Chest. 2017 Aug;152(2):343-352. doi: 10.1016/j.chest.2017.05.004. Epub 2017 May 12.

23.

Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.

Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S.

Postgrad Med. 2017 Aug;129(6):598-604. doi: 10.1080/00325481.2017.1321945. Epub 2017 Apr 28.

PMID:
28427296
24.

Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes.

Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E, Hillas G, Koulouris N, Papiris S, Papaioannou AI.

Allergy. 2017 Nov;72(11):1761-1767. doi: 10.1111/all.13184. Epub 2017 May 11.

PMID:
28407269
25.

Massive hemoptysis in a patient with pulmonary embolism, a real therapeutic conundrum.

Herodotou Y, Papaioannou AI, Karakatsani A, Reppas L, Manali ED, Apollonatou V, Tomos I, Brountzos E, Papiris S.

Respir Med Case Rep. 2017 Feb 28;20:179-183. doi: 10.1016/j.rmcr.2017.02.013. eCollection 2017.

26.

Unilateral hypertransparency on chest radiograph: the congenital Poland Syndrome.

Tomos I, Papaioannou AI, Vlami A, Apollonatou V, Manali ED, Papiris SA.

Adv Respir Med. 2016;84(6):342-343. doi: 10.5603/ARM.2016.0045.

27.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Nov;46(11):1498. doi: 10.1111/cea.12825. No abstract available.

PMID:
27790845
28.

Oxidative stress dependent microRNA-34a activation via PI3Kα reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells.

Baker JR, Vuppusetty C, Colley T, Papaioannou AI, Fenwick P, Donnelly L, Ito K, Barnes PJ.

Sci Rep. 2016 Oct 21;6:35871. doi: 10.1038/srep35871.

29.

Quantitative computed tomography: what does airway obstruction look-like?

Kallieri M, Papaioannou AI, Kostikas K, Bakakos P, Loukides S.

J Thorac Dis. 2016 Sep;8(9):E1044-E1046. No abstract available.

30.

The role of endosomal toll-like receptors in asthma.

Papaioannou AI, Spathis A, Kostikas K, Karakitsos P, Papiris S, Rossios C.

Eur J Pharmacol. 2017 Aug 5;808:14-20. doi: 10.1016/j.ejphar.2016.09.033. Epub 2016 Sep 24. Review.

PMID:
27677226
31.

25-hydroxyvitamin D in malignant pleural disease: a prospective cohort study.

Panagiotou M, Papaioannou AI, Kostikas K, Takou A, Paraskeva M, Kalkanis A, Diamantea F, Kastanakis E, Maropoulos G, Filaditaki V, Karagianidis N.

Clin Respir J. 2018 Feb;12(2):467-473. doi: 10.1111/crj.12540. Epub 2016 Aug 22.

PMID:
27502152
32.

Predictors of future exacerbation risk in patients with asthma.

Papaioannou AI, Kostikas K, Bakakos P, Papaporfyriou A, Konstantellou E, Hillas G, Papatheodorou G, Koulouris NG, Papiris S, Loukides S.

Postgrad Med. 2016 Sep;128(7):687-92. doi: 10.1080/00325481.2016.1220807. Epub 2016 Aug 17.

PMID:
27494758
33.

Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract.

Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Kolilekas L, Borie R, Bouros D, Papiris SA.

Respir Med. 2016 Aug;117:14-26. doi: 10.1016/j.rmed.2016.05.005. Epub 2016 May 7. Review.

34.

Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE).

Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Spathis A, Mazioti A, Tomos I, Papanikolaou I, Loukides S, Chainis K, Karakitsos P, Griese M, Papiris S.

PLoS One. 2016 Jun 23;11(6):e0157789. doi: 10.1371/journal.pone.0157789. eCollection 2016.

35.

Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?

Tsilogianni Z, Ntontsi P, Papaioannou AI, Bakakos P, Loukides S.

Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):1-9. doi: 10.1007/s00005-016-0407-9. Epub 2016 Jun 8. Review.

PMID:
27271573
36.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Jul;46(7):923-31. doi: 10.1111/cea.12729. Epub 2016 May 3. Erratum in: Clin Exp Allergy. 2016 Nov;46(11):1498.

PMID:
26990030
37.

Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations.

Papaioannou AI, Bartziokas K, Papiris S, Loukides S, Kostikas K.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):698-700. doi: 10.1164/rccm.201511-2141LE. No abstract available.

PMID:
26977972
38.

Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach.

Papiris SA, Kagouridis K, Kolilekas L, Papaioannou AI, Roussou A, Triantafillidou C, Baou K, Malagari K, Argentos S, Kotanidou A, Karakatsani A, Manali ED.

BMC Pulm Med. 2015 Dec 14;15:162. doi: 10.1186/s12890-015-0146-4.

39.

Cardiovascular risk in pulmonary alveolar proteinosis.

Manali ED, Papadaki G, Konstantonis D, Tsangaris I, Papaioannou AI, Kolilekas L, Schams A, Kagouridis K, Karakatsani A, Orfanos S, Griese M, Papiris SA.

Expert Rev Respir Med. 2016 Feb;10(2):235-40. doi: 10.1586/17476348.2016.1116389. Epub 2015 Nov 27.

PMID:
26558331
40.

Surfactant Proteins in Smoking-Related Lung Disease.

Papaioannou AI, Papiris S, Papadaki G, Manali ED, Roussou A, Spathis A, Karakitsos P, Kostikas K.

Curr Top Med Chem. 2016;16(14):1574-81. Review.

PMID:
26420367
41.

Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype.

Konstantellou E, Papaioannou AI, Loukides S, Patentalakis G, Papaporfyriou A, Hillas G, Papiris S, Koulouris N, Bakakos P, Kostikas K.

Respir Med. 2015 Nov;109(11):1404-9. doi: 10.1016/j.rmed.2015.09.009. Epub 2015 Sep 21.

42.

Control of asthma in real life: still a valuable goal?

Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M.

Eur Respir Rev. 2015 Jun;24(136):361-9. doi: 10.1183/16000617.00001615. Review.

43.

Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?

Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K.

Eur Respir J. 2015 Sep;46(3):846-9. doi: 10.1183/09031936.00237014. Epub 2015 Apr 16. No abstract available.

44.

Pulmonary alveolar proteinosis: time to shift?

Papiris SA, Tsirigotis P, Kolilekas L, Papadaki G, Papaioannou AI, Triantafillidou C, Papaporfyriou A, Karakatsani A, Kagouridis K, Griese M, Manali ED.

Expert Rev Respir Med. 2015 Jun;9(3):337-49. doi: 10.1586/17476348.2015.1035259. Epub 2015 Apr 12. Review.

PMID:
25864717
45.

'Every breath you take I'll be watching you': measuring exercise kinetics during 6-min walking test in COPD.

Papaioannou AI, Orfanos SE.

Respiration. 2014;88(6):449-50. doi: 10.1159/000368372. Epub 2014 Oct 25. No abstract available.

46.

The epidemiology of pulmonary nontuberculous mycobacteria: data from a general hospital in Athens, Greece, 2007-2013.

Panagiotou M, Papaioannou AI, Kostikas K, Paraskeua M, Velentza E, Kanellopoulou M, Filaditaki V, Karagiannidis N.

Pulm Med. 2014;2014:894976. doi: 10.1155/2014/894976. Epub 2014 Jun 10.

47.

Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score.

Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A, Papaioannou AI.

Respir Care. 2014 Nov;59(11):1679-86. doi: 10.4187/respcare.03171. Epub 2014 Jun 24.

48.

Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Papiris SA, Tsirigotis P, Kolilekas L, Papadaki G, Papaioannou AI, Triantafillidou C, Papaporfyriou A, Karakatsani A, Kagouridis K, Griese M, Manali ED.

Clin Drug Investig. 2014 Aug;34(8):553-64. doi: 10.1007/s40261-014-0208-z.

PMID:
24890235
49.

Collateral damage: depressive symptoms in the partners of COPD patients.

Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K.

Lung. 2014 Aug;192(4):519-24. doi: 10.1007/s00408-014-9595-4. Epub 2014 May 11.

PMID:
24816968
50.

Sex discrepancies in COPD patients and burden of the disease in females: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study).

Papaioannou AI, Bania E, Alexopoulos EC, Mitsiki E, Malli F, Gourgoulianis KI.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 17;9:203-13. doi: 10.2147/COPD.S52500. eCollection 2014.

Supplemental Content

Loading ...
Support Center